The global in-silico drug discovery market was valued at US$3.3 billion in 2024 and is projected to reach US$6 billion by 2030, expanding at a 10.3% CAGR, according to a ResearchAndMarkets.com report added on Sept. 30, 2026. Adoption is increasing among pharmaceutical companies, biotechnology firms, contract research organizations and academic institutions as computational platforms support target identification, virtual screening, lead optimization, toxicity prediction and drug repurposing. The report covers software, Software as a Service and Consultancy as a Service, with the latter forecast to grow at a 9.4% CAGR and Software as a Service projected to reach US$3.6 billion by 2030 at an 11.2% CAGR. The United States market was valued at US$871.6 million in 2024, while China is forecast to expand at a 9.9% CAGR and reach US$945.7 million by 2030.